Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.
AIMS
The aim of this study was to assess the effectiveness and safety of ospemifene in the improvement of overactive bladder (OAB) symptoms in postmenopausal women affected by vulvovaginal atrophy (VVA).


METHODS
Forty-six postmenopausal patients affected by VVA with OAB syndrome were enrolled for the study. All patients received Ospemifene 60 mg for 12 weeks. Clinical examination, 3-day voiding diary, urodynamic testing, ultrasound measurement of endometrial and bladder wall thickness (BWT) and the Vaginal Health Index (VHI) were performed at baseline and 12 weeks. Patients completed the OAB-Q SF and UDI-6.


RESULTS
After 12-weeks, the number of patients with detrusor overactivity decreased from 39% to 13% (p = 0.04). The reduction in the mean number in 24 h of voids (9.57 ± 2.12 vs. 6.63 ± 1.22, p < 0.0001), urgent micturition episodes/24 h (5.63 ± 1.46 vs. 1.44 ± 1.31, p < 0.0001), nocturia episodes (3.17 ± 0.85 vs. 1.11 ± 1.18, p < 0.0001), urinary incontinence episodes/24 h (0.85 ± 0.96 vs. 0.33 ± 0.64, p = 0.003) was observed. The UDI-6, OAB-Q symptoms, OAB-Q (HRQL) scores were 8.95 ± 0.91 vs. 5.56 ± 1.40, 62.60 ± 14.70 vs. 20.08 ± 10.83 and 18.71 ± 7.41 vs. 79.45 ± 14.47 (p < 0.001) before and after 12 weeks.


CONCLUSION
Ospemifene is an effective potential therapy for postmenopausal women with VVA improving OAB symptoms and quality of life.
['Schiavi|Michele Carlo|MC|', 'Zullo|Marzio Angelo|MA|', 'Faiano|Pierangelo|P|', "D'Oria|Ottavia|O|", 'Prata|Giovanni|G|', 'Colagiovanni|Vanessa|V|', 'Giannini|Andrea|A|', 'Di Tucci|Chiara|C|', 'Perniola|Giorgia|G|', 'Di Donato|Violante|V|', 'Monti|Marco|M|', 'Muzii|Ludovico|L|', 'Benedetti Panici|Pierluigi|P|']
D005260:Female D005831:Genital Diseases, Female D006801:Humans D008875:Middle Aged D017698:Postmenopause D012189:Retrospective Studies D013629:Tamoxifen D053201:Urinary Bladder, Overactive
vulvovaginal atrophy ospemifene overactive bladder urodynamic testing Menopause